Back to discover

Protein / target

Zinc finger E-box-binding homeobox 2

Encoded byZEB2O60315Homo sapiensSwiss-Prot
UniProt: O60315Ensembl: ENSG00000169554HGNC: HGNC:14881NCBI Gene: 9839
Antibody-tractable
Druggability
GO CC high conf
1
Research papers

Protein at a glance

Biological role

Phosphatase regulator

Strongest disease association

Genetic Diseases, Inborn

Via encoding gene ZEB2 · Genetic evidence · score 0.90

Research activity

Emerging research

1 papers · latest 2008

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters.

View complete UniProt function annotation

Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters (PubMed:16061479, PubMed:20516212). Represses transcription of E-cadherin (PubMed:16061479). Represses expression of MEOX2 (PubMed:20516212)

Subcellular location

NucleusChromosome
Domains and Gene Ontology detail (37)

Gene Ontology

  • Cchromatin
  • Cnucleolus
  • Cnucleoplasm
  • Cnucleus
  • FDNA-binding transcription activator activity, RNA polymerase II-specific
  • FDNA-binding transcription factor activity, RNA polymerase II-specific
  • FDNA-binding transcription repressor activity, RNA polymerase II-specific
  • Fphosphatase regulator activity
  • FR-SMAD binding
  • FRNA polymerase II cis-regulatory region sequence-specific DNA binding
  • Fzinc ion binding
  • Pastrocyte activation

1214 aa · 136 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOTranscriptional regulationUniProt · GOImmune signallingGO
View supporting evidence

Cell migration

  • ·endothelial cell migration

Transcriptional regulation

  • ·Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters…
  • ·DNA-binding transcription activator activity, RNA polymerase II-specific
  • ·DNA-binding transcription factor activity, RNA polymerase II-specific
  • ·DNA-binding transcription repressor activity, RNA polymerase II-specific

Immune signalling

  • ·pyroptotic inflammatory response
  • ·regulation of myofibroblast cell apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene ZEB2

Gene-level evidence surfaced through the gene ZEB2 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Genetic Diseases, Inborn
0.90Well supported

Genetic evidence dominant · Open Targets 0.55

Coronary Artery Disease
0.81Well supported

Genetic evidence dominant · Open Targets 0.50

Neurodevelopmental Disorders
0.75Well supported

Genetic evidence dominant · Open Targets 0.46

Diabetes Mellitus
0.74Moderately supported

Genetic evidence dominant · Open Targets 0.45

Heart Failure
0.74Moderately supported

Genetic evidence dominant · Open Targets 0.45

View evidence synthesis (5)
Genetic Diseases, InbornWell supported
0.90
agreement 0.77–1.00
Genetic99%Literature1%

Open Targets aggregate 0.55 · 2 independent evidence families

Coronary Artery DiseaseWell supported
0.81
agreement 0.68–0.95
Genetic94%Literature6%

Open Targets aggregate 0.50 · 2 independent evidence families

Neurodevelopmental DisordersWell supported
0.75
agreement 0.61–0.89
Genetic99%Literature1%

Open Targets aggregate 0.46 · 2 independent evidence families

Diabetes MellitusModerately supported
0.74
agreement 0.60–0.88
Genetic98%Literature2%

Open Targets aggregate 0.45 · 2 independent evidence families

Heart FailureModerately supported
0.74
agreement 0.60–0.88
Genetic98%Literature2%

Open Targets aggregate 0.45 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Genetic Diseases, Inborn0.55
Coronary Artery Disease0.50
Neurodevelopmental Disorders0.46
Diabetes Mellitus0.45
Heart Failure0.45
Hypertension0.42
Diabetes Mellitus, Type 20.42
Migraine Disorders0.41

Tractability

Antibodies — Emerging

Feasibility evidence (go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
AB · GO CC high confPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2008

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.1,810 cites

Park SM · Genes & development · 2008

Recent

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

Park SM · Genes & development · 2008

Europe PMC papers linked directly to this protein.